Emerging Strategies in Mesenchymal Stem Cell-Based Cardiovascular Therapeutics

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2024 May 24

PMID 38786076

Authors

Rishabh Kumar

Nitin Mishra

Talan Tran

Munish Kumar

Sivakumar Vijayaraghavalu

Narasimman Gurusamy

Affiliations

Soon will be listed here.

Abstract

Cardiovascular diseases continue to challenge global health, demanding innovative therapeutic solutions. This review delves into the transformative role of mesenchymal stem cells (MSCs) in advancing cardiovascular therapeutics. Beginning with a historical perspective, we trace the development of stem cell research related to cardiovascular diseases, highlighting foundational therapeutic approaches and the evolution of cell-based treatments. Recognizing the inherent challenges of MSC-based cardiovascular therapeutics, which range from understanding the pro-reparative activity of MSCs to tailoring patient-specific treatments, we emphasize the need to refine the pro-regenerative capacity of these cells. Crucially, our focus then shifts to the strategies of the fourth generation of cell-based therapies: leveraging the secretomic prowess of MSCs, particularly the role of extracellular vesicles; integrating biocompatible scaffolds and artificial sheets to amplify MSCs' potential; adopting three-dimensional ex vivo propagation tailored to specific tissue niches; harnessing the promise of genetic modifications for targeted tissue repair; and institutionalizing good manufacturing practice protocols to ensure therapeutic safety and efficacy. We conclude with reflections on these advancements, envisaging a future landscape redefined by MSCs in cardiovascular regeneration. This review offers both a consolidation of our current understanding and a view toward imminent therapeutic horizons.

Citing Articles

Assessment of the Capability of Mesenchymal Stem Cells and/or Pyrroloquinoline Quinone in Compensating the Age-Related Dysfunctions of AMP-Activated Protein Kinase Pathway in Wistar Rats.

Al Nishilli K, El Zayat E, Abdelgayed S, Hosney M, Hassan N Cell Biochem Biophys. 2025; .

PMID: 40048044 DOI: 10.1007/s12013-025-01693-7.

References

Xu H, Yang Y, Qian H, Tang Y, Wang H, Zhang Q . Rosuvastatin treatment activates JAK-STAT pathway and increases efficacy of allogeneic mesenchymal stem cell transplantation in infarcted hearts. Circ J. 2011; 75(6):1476-85. DOI: 10.1253/circj.cj-10-1275. View

Bartunek J, Behfar A, Dolatabadi D, Vanderheyden M, Ostojic M, Dens J . Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. J Am Coll Cardiol. 2013; 61(23):2329-38. DOI: 10.1016/j.jacc.2013.02.071. View

Raman N, Imran S, Ahmad Amin Noordin K, Wan Kamarul Zaman W, Nordin F . Mechanotransduction of mesenchymal stem cells (MSCs) during cardiomyocytes differentiation. Heliyon. 2022; 8(11):e11624. PMC: 9678689. DOI: 10.1016/j.heliyon.2022.e11624. View

He F, Luo P, Tang T, Zhang F, Fang H, Ji S . Targeted release of stromal cell-derived factor-1α by reactive oxygen species-sensitive nanoparticles results in bone marrow stromal cell chemotaxis and homing, and repair of vascular injury caused by electrical burns. PLoS One. 2018; 13(3):e0194298. PMC: 5847229. DOI: 10.1371/journal.pone.0194298. View

Bartunek J, Terzic A, Davison B, Filippatos G, Radovanovic S, Beleslin B . Cardiopoietic cell therapy for advanced ischaemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial. Eur Heart J. 2016; 38(9):648-660. PMC: 5381596. DOI: 10.1093/eurheartj/ehw543. View

Pachon-Pena G, Serena C, Ejarque M, Petriz J, Duran X, Oliva-Olivera W . Obesity Determines the Immunophenotypic Profile and Functional Characteristics of Human Mesenchymal Stem Cells From Adipose Tissue. Stem Cells Transl Med. 2016; 5(4):464-75. PMC: 4798735. DOI: 10.5966/sctm.2015-0161. View

Terashvili M, Bosnjak Z . Stem Cell Therapies in Cardiovascular Disease. J Cardiothorac Vasc Anesth. 2018; 33(1):209-222. PMC: 6203676. DOI: 10.1053/j.jvca.2018.04.048. View

Peressotti S, Koehl G, Goding J, Green R . Self-Assembling Hydrogel Structures for Neural Tissue Repair. ACS Biomater Sci Eng. 2021; 7(9):4136-4163. PMC: 8441975. DOI: 10.1021/acsbiomaterials.1c00030. View

Volarevic V, Markovic B, Gazdic M, Volarevic A, Jovicic N, Arsenijevic N . Ethical and Safety Issues of Stem Cell-Based Therapy. Int J Med Sci. 2018; 15(1):36-45. PMC: 5765738. DOI: 10.7150/ijms.21666. View

10.

Gnecchi M, He H, Liang O, Melo L, Morello F, Mu H . Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med. 2005; 11(4):367-8. DOI: 10.1038/nm0405-367. View

11.

Huang Y, Wu Q, Tam P . Immunomodulatory Mechanisms of Mesenchymal Stem Cells and Their Potential Clinical Applications. Int J Mol Sci. 2022; 23(17). PMC: 9456387. DOI: 10.3390/ijms231710023. View

12.

Salerno A, Netti P . Review on Computer-Aided Design and Manufacturing of Drug Delivery Scaffolds for Cell Guidance and Tissue Regeneration. Front Bioeng Biotechnol. 2021; 9:682133. PMC: 8264554. DOI: 10.3389/fbioe.2021.682133. View

13.

Silveira B, Ribeiro T, Freitas R, Carreira A, Goncalves M, Sogayar M . Secretome from human adipose-derived mesenchymal stem cells promotes blood vessel formation and pericyte coverage in experimental skin repair. PLoS One. 2022; 17(12):e0277863. PMC: 9762598. DOI: 10.1371/journal.pone.0277863. View

14.

Olsen T, Ng K, Lock L, Ahsan T, Rowley J . Peak MSC-Are We There Yet?. Front Med (Lausanne). 2018; 5:178. PMC: 6021509. DOI: 10.3389/fmed.2018.00178. View

15.

Liang S, Su Y, Yao R . 3D Bioprinting of Induced Pluripotent Stem Cells and Disease Modeling. Handb Exp Pharmacol. 2023; 281:29-56. DOI: 10.1007/164_2023_646. View

16.

Martin-Piedra M, Garzon I, Oliveira A, Alfonso-Rodriguez C, Carriel V, Scionti G . Cell viability and proliferation capability of long-term human dental pulp stem cell cultures. Cytotherapy. 2014; 16(2):266-77. DOI: 10.1016/j.jcyt.2013.10.016. View

17.

Nicolas J, Magli S, Rabbachin L, Sampaolesi S, Nicotra F, Russo L . 3D Extracellular Matrix Mimics: Fundamental Concepts and Role of Materials Chemistry to Influence Stem Cell Fate. Biomacromolecules. 2020; 21(6):1968-1994. DOI: 10.1021/acs.biomac.0c00045. View

18.

Xu S, Qiu Y, Tao J . The challenges and optimization of cell-based therapy for cardiovascular disease. J Transl Int Med. 2022; 9(4):234-238. PMC: 8802397. DOI: 10.2478/jtim-2021-0017. View

19.

Silva D, Souza B, Vasconcelos J, Azevedo C, Valim C, Paredes B . Granulocyte-Colony Stimulating Factor-Overexpressing Mesenchymal Stem Cells Exhibit Enhanced Immunomodulatory Actions Through the Recruitment of Suppressor Cells in Experimental Chagas Disease Cardiomyopathy. Front Immunol. 2018; 9:1449. PMC: 6036245. DOI: 10.3389/fimmu.2018.01449. View

20.

Mitrecic D, Nicaise C, Klimaschewski L, Gajovic S, Bohl D, Pochet R . Genetically modified stem cells for the treatment of neurological diseases. Front Biosci (Elite Ed). 2011; 4(3):1170-81. DOI: 10.2741/449. View